Stentys is a French-headquartered medical technology company commercialising the world’s first and only self-apposing stent to treat Acute Myocardial Infarction (AMI). The company has announced the European commercial release of an enhanced stent-delivery system for its Self-Apposing® stent. The change involves use of a new catheter to implant the stent, which has a hydrophilic coating and an ergonomic handle that considerably facilitates stent implantation in tortuous vessels.
Stents are implanted in the coronary arteries via a keyhole in the groin or in the wrist under angiography (X-ray imaging). Cardiologists use a delivery catheter to navigate through the arteries, reach the occluded vessel and deploy the stent.
In its latest guidelines on AMI treatment, the European Society of Cardiology (ESC) calls attention to the importance of selecting the appropriate stent size, as the vessel in this setting is contracted and contains thrombus, and to the complications that may result from inappropriate stent sizing. Stentys says its Self- Apposing® Stent solves that “stent-sizing dilemma” by fitting into the contour of a blood vessel, and its shape and diameter adapt as the vessel dilates and the initial clot dissolves during the post-AMI phase.
Stentys’s Self-Apposing® Stents are designed to adapt to vessels with ambiguous or fluctuating diameters, particularly in the post-infarction phase, in order to prevent the malapposition problems associated with conventional stents. In the APPOSITION III clinical trial, Stentys stents demonstrated a very low one-month mortality rate among 1,000 high-risk AMI patients when compared to recent studies with conventional stents.
Gonzague Issenmann, Chief Executive Officer and co-founder of STENTYS, commented: “Feedback from cardiologists suggests the new delivery catheter is very user-friendly and we are confident this product enhancement will allow a greater range of patients to benefit from our STENTYS Self-Apposing stent technology.”